Search - tctmd.com

Displaying 81 - 100 of 7389

Sort: Relevancy | Date

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

November 08, 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

News Conference News AHA 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

November 08, 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

SAVE-PCI: Small-Bore Percutaneous VAD Matches IABP in High-risk PCI

News Conference News TCT 2025

SAVE-PCI: Small-Bore Percutaneous VAD Matches IABP in High-risk PCI

November 06, 2025

Heavy Alcohol Use Tied to More-Severe Intracerebral Hemorrhages

News Daily News

Heavy Alcohol Use Tied to More-Severe Intracerebral Hemorrhages

November 06, 2025

‘Investing’ in CTOs With Staged PCI Seems to Pay Off in Safety Gains

News Conference News TCT 2025

‘Investing’ in CTOs With Staged PCI Seems to Pay Off in Safety Gains

Yael L. Maxwell

November 05, 2025

What’s Going to Be Hot at AHA 2025?

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

PREVENT-TAHA8: Post-MI Intracoronary Stem Cells May Lower HF Risk After STEMI

News Daily News

PREVENT-TAHA8: Post-MI Intracoronary Stem Cells May Lower HF Risk After STEMI

November 04, 2025

What Makes MedTech Great—or Not—and Envisioning Its Future

News Conference News TCT 2025

What Makes MedTech Great—or Not—and Envisioning Its Future

November 04, 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure ANDES

News Conference News TCT 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES

Yael L. Maxwell

November 04, 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

TCTMD’s Top 10 Most Popular Stories for October 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2025

November 03, 2025

AI-ECG Finds STEMI Faster, Cuts False-Positive Cath Lab Activations

News Conference News TCT 2025

AI-ECG Finds STEMI Faster, Cuts False-Positive Cath Lab Activations

October 31, 2025

News Industry News

SMT’s Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across Key Global Studies Presented at TCT 2025

October 29, 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

iFR-Guided Immediate PCI Not Superior to Deferred CMR-Guided Strategy in STEMI

News Conference News TCT 2025

iFR-Guided Immediate PCI Not Superior to Deferred CMR-Guided Strategy in STEMI

Yael L. Maxwell

October 28, 2025

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

News Conference News TCT 2025

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

Michael O'Riordan

October 28, 2025

Presentation TCT 2025

TCT 631: Transcatheter Aortic Valve Implantation In Low And Intermediate Risk Septuagenarians With Risk Factors Not Captured By The Traditional Surgical Risk Scores

Presenter: Andreas Synetos

October 28, 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

News Conference News TCT 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

October 27, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.